Oppenheimer cuts Avalo Therapeutics price target on trial concerns
Covered in this story
What has happened since
- Avalo Therapeutics is down 2.1% since this was published, 10 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Oppenheimer’s $16 target on $AVTX is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Oppenheimer’s track record →Call it yourself
No member calls on $AVTX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Avalo Therapeutics →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.